Recombinant Human TREML2/TLT-2 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TREML2/TLT-2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. Human PBMC cultured for 72 hours with PHA were incubated for an additional 3 days in 96 well plates coated with anti-CD3 and recombinant human TREML2/Fc Chimera.
  The ED₅₀ for this effect is 0.45-1.8 μg/mL.
  Optimal dilutions should be determined by each laboratory for each applications.
• Source: Mouse myeloma cell line, NS0-derived human TREML2/TLT-2 protein
  

  Human TREML2 (Gly78 - Ser327) Accession # CAI19909	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: CAI19909
• N-terminal Sequence: Gly78
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: TREML2
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 53.7 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75-100 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TREML2/TLT-2 Fc Chimera Protein, CF

• C6orf76
• dJ238O23.1
• FLJ13693
• MGC149715
• MGC149716
• TLT2
• TLT-2
• TREML2
• trem-like transcript 2 protein
• triggering receptor expressed on myeloid cells-like 2
• triggering receptor expressed on myeloid cells-like protein 2
• UNQ6268/PRO20473

Background

Trem-like transcript 2 protein (TLT-2; also TREML2) is a 33 kDa (unglycosylated) type I transmembrane cell surface receptor and member of the Trem family of receptor proteins. Human TLT-2 is synthesized as a 321 amino acid (aa) precursor that contains an 18 aa signal sequence, a 250 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 32 aa cytoplasmic tail (SwissProt # Q5T2D2). Within the ECD are an Ig-like V-type domain (aa 20 ‑ 121) and one potential site of N-linked glycosylation. Mature human TLT-2 shares 49% aa sequence identity with mature mouse TLT-2. Cell surface expression of TLT-2 is seen for most of the B and myeloid cell lines (1 ‑ 2). TLT-2 is also expressed constitutively on CD8+ T cells and induced on CD4+ T cells after activation (2). TLT-2 plays a role in the innate and adaptive immune responses. In 2008, Hashiguchi et al. discovered that the B7 family member B7-H3, which also plays important roles in immune responses, specifically bound to TLT-2. According to their research, stimulation with B7-H3 transfectants preferentially up-regulated the proliferation and IFN-gamma production on CD8+ T cells (2). Also, transduction of TLT-2 into T cells resulted in enhanced IL-2 and IFN-gamma production via interactions with B7-H3, and blockade of the B7‑H3:TLT‑2 pathway with mAb against B7-H3 or TLT-2 efficiently inhibited contact hypersensitivity responses (2). In 2009, however, Leitner et al. extensively analyzed interaction of B7-H3 with TLT-2 and found no evidence for such an interaction (3).

1. King, R.G. et al. (2006) J. Immunol. 176:6012.
2. Hashiguchi, M. et al. (2008) Proc. Natl. Acad. Sci. U.S.A. 105:10495.
3. Leitner, J. et al. (2009) Eur. J. Immunol. 39:1754.

Publications for TREML2/TLT-2 (3259-TL)(3)

Publications using 3259-TL

• J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity Nature Communications, 2022-03-25;13(1):1606. 2022-03-25 [PMID: 35338135] (Flow Cytometry, Human)
• Leitner , Judith, Rieger , Armin, Pickl , Winfried, Zlabinger , Gerhard, Grabmeier-Pfistershammer , Katharin, Steinberger , Peter TIM-3 does not act as a receptor for galectin-9. PLoS Pathog, 2013-03-21;9(3):e1003253. 2013-03-21 [PMID: 23555261] (Bioassay, Mouse)
• de Freitas A, Banerjee S, Xie N Identification of TLT2 as an engulfment receptor for apoptotic cells. J. Immunol., 2012-05-09;188(12):6381-8. 2012-05-09 [PMID: 22573805] (In Vivo, Mouse)

Bioinformatics

• Gene Symbol: TREML2
• Uniprot:
  • CAI19909()